anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fifty-one percent of humans are born with ovaries. As the ovarian production of estrogen diminishes in midlife and ultimately stops, it is estimated that more than 47 million women worldwide enter the menopause transition annually. More than 70% will experience musculoskeletal symptoms and 25% will be disabled by them through the transition from perimenopause to postmenopause. This often-unrecognized collective of musculoskeletal symptoms, largely influenced by estrogen flux, includes arthralgia, loss of muscle mass, loss of bone density and progression of osteoarthritis, among others. In isolation, it can be difficult for clinicians and patients to adequately appreciate the substantial role of decreasing estrogen, anticipate the onset of related symptoms and actively treat to mitigate future detrimental processes. Thus, in this review we introduce a new term, the musculoskeletal syndrome of menopause, to describe the collective musculoskeletal signs and symptoms associated with the loss of estrogen. Given the significant effects of these processes on quality of life and the associated personal and financial costs, it is important for clinicians and the women they care for to be aware of this terminology and the constellation of musculoskeletal processes for which proper risk assessment and prophylactic management are of consequence.
PURPOSE: A transmucosal delivery system formed by the combination of a material and C5a ligand is provided to enable specific entrance of the target material into mucous. CONSTITUTION: A transmucosal delivery system is formed by the combination of a material and C5aR ligand. The ligand is alpha helix of coat protein H of Yersinia enterocolotica. The material is a drug, nutrient, gene, vaccine, protein, organic chemical, or inorganic chemical. The material is used by oral administration. A pharmaceutical composition contains the delivery system as an active ingredient.
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS). Clinically isolated syndrome (CIS) is often a sign of multiple sclerosis and the term refers to the first episode of neurologic symptoms experienced by a patient. Possible presentations of CIS include optic neuritis, a brain stem and/or cerebellar syndrome, a spinal cord syndrome, or occasionally cerebral hemispheric dysfunction. An accurate diagnosis at this time is important because people with a high risk of developing MS are encouraged to begin treatment in order to delay or prevent a second neurologic episode and, therefore, the onset of MS.

The innate and adaptative immune systems play an important role in pathophysiology of MS, acting in interaction with environmental, genetic, and epigenetic factors.

Epigenetic modifications, such as DNA methylation and histone modification, alter DNA accessibility and chromatin structure, thereby regulating patterns of gene expression. These processes are crucial to normal development and differentiation of distinct cell lineages in the adult organism. Histone acetylation, through the family of histone acetyl transferase (HAT), is most consistently associated with promoting transcription. Deacetylation of histones correlates with CpG methylation and the inactive state of chromatin. There are 4 classes of histone deacetylase enzymes (HDACs), with members capable of deacetylation of histones and/or other protein targets. Acetylation homeostasis is a key regulator of both immune cell activation. Of note, potent histone deacetylase inhibitors (HDACi) endowed with antiinflammatory and neuroprotective properties have been identified. Efficacy of HDACi in experimental models of MS has been reported consistently. This study could provide information on the mechanisms involved.
In forensic medicine, estimating the postmortem interval (PMI) is of great importance for the timeline and the reconstruction of the events surrounding death. Bone marrow (BM) is one of the largest organs in the body, with good resistance to autolysis and contamination. Therefore, the present study aims to correlate different postmortem intervals and bone marrow antioxidant enzyme levels using an Enzyme-linked immunosorbent assay (ELISA). In addition, detection of the changes in the histological structure of human bone marrow in relation to the time passed since death. BM samples from 20 forensic autopsy cadavers were obtained from cases referred to the Department of Forensic Medicine in the Ministry of Justice, Dakahlia Governorate, processed for histopathological examination as well as estimation of reduced glutathione (GSH), glutathione peroxidase (GPX), and glutathione reductase (GRX) using ELISA. Results of ELISA analysis showed a significant decrease in the level of antioxidant enzymes with increasing PMI; regarding histopathological examination, from 6 to > 18 h PMI, the changes in morphology after death were gradual, progressive, and regular, indicating great value in PMI determination. Also, 18 h of PMI showed loss of cellular details, absence of fat cells, and necrosis of BM with the nucleus dispersed as eosinophilic debris. Estimation of antioxidant enzymes level in human bone marrow using ELISA and detection of the changes in the histological structure of human bone marrow in relation to time passed since the death, either separately or in combination, can be used to estimate PMI accurately.
The intervention to experimental/intervention group will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; and third, end-line survey at 12 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance. Patients will be able to view the educational material in the pharmacy via a tablet, since audio-visual presentations make learning easier. The intervention group will receive phone call intervention at 3 months and 6 months.
Small extracellular vesicles (sEVs) residing at tumor tissues are valuable specimens for biopsy. Tumor heterogeneity is common across all cancer types, but the heterogeneity of tumor tissue-derived sEVs (Ti-sEVs) is undefined. This study aims to discover the spatial distributions of Ti-sEVs in oral squamous cell carcinoma (OSCC) tissues and explore how these vesicle distributions affect the patients' prognosis. Multi-regional sampling enabled us to uncover that Ti-sEVs' accumulation at peritumoral sites correlates with a higher disease-free survival rate, and conversely, sparse peritumoral Ti-sEVs tend to forecast a higher risk of relapse. Of those relapsed patients, Ti-sEVs strongly bind to extracellular matrix and subsequently degrade it for allowing themselves enter the bloodstream rather than staying in situ. In advanced OSCC patients, the quantity and spatial distribution of Ti-sEVs prior to anti-PD-1 treatment, as well as the temporal variance of Ti-sEVs before and after immunotherapy, strongly map the clinical response and can help to distinguish the patients with shrinking tumors from those with growing tumors. Our work elucidates the correlation of spatiotemporal features of Ti-sEVs with patients' therapeutic outcomes and exhibit the potential for using Ti-sEVs as a predictor to forecast prognosis and screen the responders to anti-PD-1 therapy.
BACKGROUND-OBJECTIVE(S): This randomized, split-mouth study aimed to compare postoperative complications following the surgical extraction of impacted lower third molars using piezosurgery versus conventional rotary instruments.
MATERIALS AND METHODS: Twenty-one patients, aged 18-35 years, with bilaterally and symmetrically impacted lower third molars, were randomly assigned to undergo extraction using piezosurgery on one side and conventional rotary instruments on the other.
RESULTS: The piezosurgery method required a longer operation time. However, it resulted in quicker resolution of postoperative swelling by the 7th day compared to the conventional method, where swelling persisted longer. Mandibular angle-tragus measurements were significantly higher with the conventional method on the 1st, 3rd, and 7th postoperative days. Although mouth opening decreased significantly after piezosurgery, it returned to preoperative levels by the 7th day, outperforming the conventional method. Postoperative pain was notably higher with the conventional method during the first four days but showed no significant difference from the 5th day onward. Alveolar bone healing was significantly better with piezosurgery at the 3rd and 6th months. Temporary paresthesia occurred in one patient from the conventional group, resolving within four weeks. Neither method resulted in alveolar osteitis.
CONCLUSION(S): Within the study's limitations, piezosurgery demonstrated a reduction in postoperative discomfort, suggesting its advantage in enhancing patient recovery following lower third molar extractions.
CLINICAL SIGNIFICANCE: Piezosurgery, when used appropriately, can reduce postoperative complications compared to conventional methods. Clinicians should be aware of its indications, benefits, and potential challenges. Trial registration This study was registered as a clinical trial to the ClinicalTrials.gov, and the registration ID is NCT06262841 ( https://clinicaltrials.gov/study/NCT06262841 ).
This is a Phase 1, single centre, randomized, double-blind, placebo-controlled, single dose, parallel group study in healthy Chinese male or female subjects. 48 healthy subjects will be randomly assigned to one of the three treatment cohorts (i.e. 1:1:1 to Low dose, Medium dose and High dose) to receive a single dose of tezepelumab or placebo in a 3:1 ratio. Each subject will only participate in one cohort. Dose level is unblinded and treatment (tezepelumab or placebo) will be double-blinded within each treatment cohort. Following a screening period of a maximum of 28 days, subjects will stay at the study facility for two nights starting from the day before dosing (Day -1) to Day 2. Subjects will receive a single dose of tezepelumab or placebo subcutaneously on Day 1 and safety monitoring and serial collection of blood samples for PK evaluation will be followed throughout the study period. The follow up period after the dosing will be 112 days.
Many treatment protocols compare the strength of the injured extremity to the uninjured extremity or compare it to normative data from the same group of individuals. There is controversy about the difference in grip strength between dominant and non-dominant hands in left- and right-hand dominant individuals. There is no study in the literature that evaluates the differences in muscle strength, joint position sense and upper extremity function skills between dominant and non-dominant upper extremities between genders. It is very important to include bilateral activity training in rehabilitation programs that aim to improve upper extremity mobility and speed. In addition, it will contribute to the accurate evaluation of activity and participation limitations, the determination of priorities, the selection of the right activity in task-specific and target-oriented treatment approaches, and the achievement of more effective results when integrated with technology-supported approaches. Therefore, the aim of our study is to fill this gap in the literature by comparing the differences between dominant and non-dominant upper extremities between genders.
Nasopharyngeal carcinoma (NPC), a human malignancy derived from the nasopharyngeal epithelial cells, is occurring highly frequently in Taiwan. Of note, the average ages of NPC individuals are usually ten years younger than those of patients with other head and neck cancers. Clinically, this early onset and high incidence of metastasis in NPC may contribute to its poor prognosis. Fortunately, NPC is usually radio-and chemo-therapy sensitive during the early stage. So, the more we understand NPC pathogenesis, the more efficient detection methods would be developed for NPC early diagnosis and prognosis.

Four unique characteristics have been reported for NPC: geographic preference, heavy infiltration of lymphocytes, high incidence of metastasis and association with Epstein-Barr virus (EBV). According to our hypothesis that both cellular changes and viral factors are crucial for NPC development, four major long-term study goals have been carried out in our lab: (1) identification and characterization of the cellular and viral factors that are involved in NPC formation, (2) elucidation of potencies of these molecules as clinical diagnosis and prognosis markers of NPC, (3) investigation of the molecular and biological linkage between EBV infection and NPC development and (4) establishment of a drug-screening system for NPC chemotherapy.

Based on our assumption that both cellular genes and viral factors are involved in NPC carcinogenesis, the following genes are chosen as the major study targets in this five-year grant. Firstly, to asses the alteration of cellular gene expression, we choose three cytokine genes 【interleukin (IL)-1, IL-7 and IL-13】, three inhibitors of apoptosis proteins (IAP) genes (survivin, HIAP-1, and HIAP-2), two specific cellular genes (osteoblast-specific factor-2 and polymeric immunoglobulin receptor) and one tumor suppressor gene (tumor susceptibility gene TSG101) in our proposal. All these genes exhibit special expression profiles in NPC biopsies in our preliminary study. So, the regulation and effect of these genes in epithelial cells would be the study focus. Secondly, two EBV viral genes, Zta and LMP2A, the former encoded immediately early lytic product and the later encoded latent membrane protein, are selected for this study. In our previous grant, we found that Zta can up-regulate TKT (trk-related tyrosine kinase) and matrix metalloproteinases (MMP)-1 which is a down-stream effector of TKT. Therefore we will extend the study on how Zta and LMP2A regulate and influence anti-apoptotic network and metastasis progression. Based on our preliminary data, this proposal is highly approachable and the results may provide valuable information for NPC diagnosis, prognosis and treatment.
After clinical success of colonic stenting, patients will receive neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 3-5 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
Vitamin D levels will be measured at the time of routine blood work. If Vitamin D levels are found to be low, patients will take 50,000 IU of vitamin D3 weekly daily as maintenance therapy. There is no prospective control arm.
Psychoeducation (PSY) condition will be similar to MM with respect to number and duration of weekly sessions and daily homework. PSY is a lecture-based program based on the "10 Keys"TM to Healthy Aging Course, an evidence-based program for older adults. Each session focuses on a specific topic related to wellness (e.g., nutrition, physical activity, medical screening) and caregiver-specific topics (e.g., understanding dementia and neurodegenerative disease, legal and financial issues).
Bloodstream infections (BSI) pose a substantial threat to the well-being and survival of patients undergoing hematopoietic stem cell transplantation (HSCT). Risk factors for these infections vary across the different post-HSCT phases. In the pre-engraftment period, patients are particularly susceptible to infection due to prolonged neutropenia, mucosal damage, and extensive use of central venous line (CVL). In the post-engraftment phase, the emergence of graft versus host diseases further compounds the risk. The epidemiology of these infections has undergone notable changes over the years due to multifactorial reasons, including the evolution of protocols that intensify immunosuppression. In this context, the emergence of multi-drug resistance (MDR) microorganisms can be a challenge due to the elevated risk of mortality in these vulnerable patients. Unfortunately, there is a lack of comprehensive data on this topic, particularly in pediatrics. This article aims to provide a summary of the epidemiology of BSI in the different post-transplant phases and the impact of MDR pathogens. Having knowledge about the local epidemiology of BSI can be instrumental in tailoring targeted therapies, leading to improved survival rates in HSCT recipients.
The invention relates to a Chuanxiong Chatiao soft capsule and a preparation method thereof. In modern medicine, the Chuanxiong Chatiao powder is improved and made into tablets, capsule, oral liquid and so on, which can not achieve the efficacy of the original formulation. The preparation method of the Chuanxiong Chatiao soft capsule is that Chuanxiong, red peony root, gastrodia elata, notopterygium, angelica, asarum, chrysanthemum, mint, parsnip, tea leaves, liquorices and catnip are put into the Chinese medicine extraction pot. Water is added for soaking, and the mixture is decocted for three times. At the same time, volatile oil is collected. The water decoction liquid and extraction liquid are combined and processed with centrifugal filtration. The filtrate is decompressed and condensed, and crushed with grain size less than 120 meshes after being processed with spray drying. The extraction volatile oil is melted with a certain amount of edible oil. Dry extractum power is mixed with edible oil. The dry extractum power takes 20-50 weight percent of the oil base in soft capsule. The mixture is grinded by a colloid mill, and pigment gelatin which is taken as capsule wall material is added and is made into capsule core extractum oil base liquid. The soft capsule is formed by pressing under the condition of stirring. The soft capsule is manufactured after being dried, washed and dried. The Chuanxiong Chatiao soft capsule is used for replacing Chuanxiong Chatiao powder.
Prodn. of crystal suspensions of one or more insulin derivs. of formula (I) having an isoelectric point of 5.8-8.5 by carrying out the crystallisation in an aq. medium in the region of the isoelectric pt. of the deriv(s) in the presence of an aromatic hydroxy cpd. (R1=H or Phe; R30=residue of a neutral, genetically codable L-amino acid; R31=physiologically tolerable basic 1-50C organic gp. comprising 0-3 alpha-amino acid residues, a terminal carboxy function which may be present being in free, amide, ester or lactone form or reduced to CH2OH.
In this condition, the participant will have to think about 4 activities he will plan to do during the next 2 weeks. He will then complete a questionnaire about all the activities he identified. There is no mental imagery exercise in this condition. He then will proceed to go home and receive the assignment to do the planned activities in the course of the next two weeks. He will report in a booklet ratings of the activities he did.
Participants will be taking one liquid tincture orally per day as well as 2 capsules orally at night. At week 10, non-responders will take another supplement consisting of 2 capsules orally along with the liquid tincture until week 14.
PURPOSE: A pharmaceutical composition containing oleanolic acid acetate or a pharmaceutically acceptable salt thereof for preventing or treating TLR and IL-6 mediated diseases is provided to inhibit STAT3 transcription and phosphorylation. CONSTITUTION: A pharmaceutical composition for preventing or treating metabolic diseases contains a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The composition additionally contains a pharamaceutically acceptable carrier, excipient, or diluent. The phramceutical composition contains Phaseoli angularis semen extract or a fraction thereof as an active ingredient. The extract is isolated using water, alcohol of 1-6 carbon atoms or a mixture solvent thereof. The fraction is prepared using hexane, ethyl acetate, water, or a mixture solvent thereof.
PURPOSE:A disintegrating agent, containing a modified starch having a specific swelling degree, and having improved disintegrating and tableting properties. CONSTITUTION:A disintegrating agent containing a modified starch, e.g. obtained by processing a subterranean stem of a potato, sweet potato or tapioca, and having a swelling degree of 3.0-6.0, preferably 4.0-5.5. The modified startch is obtained by kneading a hydrated and humidified starch having a moisture of 30-60%, preferably 40-55%, in a speed kneader, etc., gelatinizing the kneaded starch under heating at 70-150, preferably 80-120 deg.C, cooling the kneaded starch to 20 deg.C or below, partially crystallizing the starch, and drying and pulverizing the crystallized starch. The amount necessary for the agent is at least 30% or more, preferably 50% or more, in the disintegrating agent, and a disintegrating agent, e.g. another starch, surfactant or calcium carboxylmethyl cellulose, may be used together.
The aim of this study is to optimise the dosing of raltegravir when coadministered intermittently with rifampicin. The co-administration of rifampicin and antiretrovirals (ARVs) is both complicated and problematic due to the potent induction of metabolism by rifampicin. Rifampicin induces cytochrome P450 (CYP) enzymes, which results in reduced plasma concentrations of two groups of ARVs, the protease inhibitors (PIs) and the non-nucleoside reverse transcriptase inhibitors (NNRTIs). This pharmacokinetic interaction precludes the use of PIs and severely compromises the effectiveness of the NNRTI, nevirapine, as it potentially results in the loss of antiviral activity due to sub-therapeutic concentrations which will also lead to antiretroviral resistance.

Rifampicin also induces phase II enzymes including UDP-glucuronosyl transferase. The HIV integrase inhibitor, raltegravir, is primarily metabolised by UGT1A1 and therefore, there is the potential for a pharmacokinetic drug interaction with rifampicin. In fact, previous studies have shown a decrease in raltegravir AUC, CMAX, and C12 when co-administered with daily rifampicin. During directly observed therapy (DOTs) for TB, rifampicin is often given intermittently (e.g. 3 times a week). Although several studies have examined the interaction between raltegravir and daily rifampicin, currently there are no data regarding the pharmacokinetics of raltegravir when rifampicin is co-administered intermittently.
1445635 Preparation of silica pigments; faujasite J M HUBER CORP 22 Aug 1973 [6 Sept 1972] 39703/73 Heading C1A Silicic acid pigments are prepared by adding acid to an alkali metal silicate solution at 100- 200‹ F. until precipitation just begins, the mole ratio silica to alkali metal oxide being 1 : 1 to 4 : 1, stopping the acid addition at this point and ageing the reaction mass for 10 minutes to 2 hours, then continuing the acid addition until precipitation is complete. The point of first precipitation, usually judged by the appearance of opalescence must be very precisely estimated; a bolometer may be used. The precipitate may be separated, dried and ground. The acid may be H 2 SO 4 , HNO 3 , HCl, acetic, formic or CO 2 . The alkali metal silicate may be Na, K or Li silicate. The concentration of the silicate solution may be 1-2À5 lbs. per US gallon. The product may be used as a raw material in molecular sieve (faujasite) production and as a filler or flatting agent for paint.